Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens

• Published in: Vaccines (Basel) Vol. 11; no. 10; p. 1585
• Main Authors: Dotiwala, Farokh, Upadhyay, Arun K
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023; MDPI
• Subjects: Adjuvants; Analysis; Antibodies; Antigens; Cell proliferation; Chemokines; Clinical trials; COVID-19; COVID-19 vaccines; Cytotoxicity; Disease transmission; Dosage and administration; Evaluation; Expression vectors; FDA approval; Humoral immunity; Immunity; Immunoglobulin A; Immunoglobulin G; Influenza; inhaled vaccines; Lymphatic system; Lymphocytes; Lymphocytes T; Mucosal immunity; Mucosal-associated lymphoid tissue; Nucleic acids; Pandemics; Pathogenic microorganisms; Pathogens; Platforms; Respiratory diseases; respiratory infections; Respiratory syncytial virus; Review; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Streptococcus infections; Vaccines; Whooping cough; United States; China; India
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11101585

Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has the potential to prevent the infection from getting established. This is different from systemic vaccination, which protects against the development of systemic symptoms. The field of mucosal vaccination has seen fewer technological advances compared to nucleic acid and subunit vaccine advances for injectable vaccine platforms. The advent of the next-generation adenoviral vectors has given a boost to mucosal vaccine research. Basic research into the mechanisms regulating innate and adaptive mucosal immunity and the discovery of effective and safe mucosal vaccine adjuvants will continue to improve mucosal vaccine design. The results from clinical trials of inhaled COVID-19 vaccines demonstrate their ability to induce the proliferation of cytotoxic T cells and the production of secreted IgA and IgG antibodies locally, unlike intramuscular vaccinations. However, these mucosal vaccines induce systemic immune responses at par with systemic vaccinations. This review summarizes the function of the respiratory mucosa-associated lymphoid tissue and the advantages that the adenoviral vectors provide as inhaled vaccine platforms.